Author of

• 20171

  +

  P2.07 - Immunology and Immunotherapy (ID 708)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Immunology and Immunotherapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 23391

    +

    P2.07-016 - Inmunotherapy:  Which Is More Important,  Choosing Patients Who Will Respond or Identifying Those Who Will Die Early? (ID 8300)

    09:30 - 16:00  |  Presenting Author(s): Inmaculada Ramos García
    • Abstract
    • Slides

    Background:
    Nivolumab has been approved in a second line, of non-small cell lung cancer (NSCLC) after the failure of the first line of platinum-based chemotherapy. The use of immunotherapy is assuming a new challenge in the clinical practice of the oncologist, who has to familiarize himself with a different toxicity profile than chemotherapy.The objective of this study is to describe the clinical characteristics of our patients, focusing on the toxicity profile found and trying to find something that will help us to identify patients who are going to have poor early evolution.
    
    Method:
    We have reviewed 49 patients treated with nivolumab, from their use in expanded access, until April 2017. Retrospective information was collected on the clinical, pathological, hematological and treatment characteristics of these patients. Statistical analysis was performed using the SPSS software version 21.0.
    
    Result:
    The characteristics of the patients are summarized in Table 1. More than half of the patients presented toxicity, in any of their grades, being approximately 56,5 % grades 1-2, and 8% grade 3. Only one patient was presented grade 4 toxicity. The different toxicities are described in Table 1. Attention is drawn to a large number of patients (23) who receive 4 or fewer cycles, who died quickly, most often in the context of rapid progression, and at other times unable to reevaluate the disease. Regardless of these patients, the time of progression was 7.6 months, and the overall survival was 12.6 months, data that can be superimposed on those seen in EECC. Figure 1
    
    
    
    Conclusion:
    Immunotherapy in NSCLC has become a basic pillar of treatment, presenting a different toxicity profile to that of chemotherapy, which we are learning to manage. We thought that it would be important, something that discard those patients who were presumed to have a rapid bad evolution.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.